Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis (HERO)
This study has been completed.
Information provided by:
First received: September 13, 2005
Last updated: August 28, 2007
Last verified: August 2007
The purpose of the study is to assess the efficacy of adalimumab in subjects with rheumatoid arthritis focusing on subject-reported outcomes and early response to treatment
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO)|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Abbott:
Primary Outcome Measures:
- Patient reported outcomes, clinical response indicators.
Secondary Outcome Measures:
- Subject reported assessments of disease activity, physician reported assessments of disease activity, safety parameters, clinical response indicators.
|Study Start Date:||August 2004|
Contacts and Locations